Publications by authors named "E Bosman"
Objective: We aimed to study the disease course, outcomes, and predictors of outcome in pediatric-onset antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) affecting the kidneys.
Methods: Patients eligible for this study had a diagnosis of granulomatosis with polyangiitis (GPA), microscopic polyangiitis, or ANCA-positive pauci-immune glomerulonephritis, were 18 years or younger at diagnosis, had renal disease defined by biopsy or dialysis dependence, and had clinical data at diagnosis and at either 12 or 24 months. Ambispective data from A Registry for Children with Vasculitis/Pediatric Vasculitis Initiative Registry was used.
Article Synopsis
- The study compares the effectiveness and toxicity of two treatments, rituximab (RTX) and cyclophosphamide (CYC), for pediatric patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).
- It analyzes data from 104 patients and finds no significant difference in remission rates or severe adverse events between the two treatment groups.
- Limitations of the study include the lack of standardized treatment protocols and the retrospective nature of the analysis.
Objectives: The objective of this study is to evaluate whether anti-neutrophil cytoplasmic antibody (ANCA) seropositivity and antigen specificity at diagnosis have predictive utility in paediatric-onset small vessel vasculitis.
Methods: Children and adolescents with small vessel vasculitis (n=406) stratified according to the absence (n=41) or presence of ANCA for myeloperoxidase (MPO) (n=129) and proteinase-3 (PR3) (n=236) were compared for overall and kidney-specific disease activity at diagnosis and outcomes between 1 and 2 years using retrospective clinical data from the ARChiVe/Paediatric Vasculitis Initiative registry to fit generalised linear models.
Results: Overall disease activity at diagnosis was higher in PR3-ANCA and MPO-ANCA-seropositive individuals compared with ANCA-negative vasculitis.
Article Synopsis
- - This study investigated using bionanovesicles for delivering a photosensitizer drug into cholangiocarcinoma cells to enhance photodynamic therapy (PDT) outcomes.
- - Two types of bionanovesicles were created from cholangiocarcinoma cells, characterized for size, stability, and efficiency, and shown to effectively deliver the photosensitizer with no toxicity associated with dark conditions.
- - The results indicated that these vesicles could successfully disperse the photosensitizer inside tumor cells and achieved higher PDT efficiency compared to traditional methods using liposomal forms.
Objective: To determine the SARS-CoV-2 seroprevalence among school workers within the Greater Vancouver area, British Columbia, Canada, after the first Omicron wave.
Design: Cross-sectional study by online questionnaire, with blood serology testing.
Setting: Three main school districts (Vancouver, Richmond and Delta) in the Vancouver metropolitan area.